Literature DB >> 30815864

Integrative analysis of OIP5-AS1/HUR1 to discover new potential biomarkers and therapeutic targets in multiple sclerosis.

Jalal Gharesouran1, Mohammad Taheri2, Arezou Sayad1, Mehrdokht Mazdeh3, Mir Davood Omrani2.   

Abstract

Multiple sclerosis (MS) is a devastating autoimmune disease of the central nervous system associated with demyelination and axonal injury. This study was designed to find potential lncRNAs and their targets that are associated with the molecular basis of MS pathogenesis. In this study, peripheral blood samples were obtained from 50 relapsing-remitting MS (RR-MS) patients and 50 healthy controls. lncRNAs and their target were selected for validation using TaqMan Real-Time PCR. Interactions were studied based on approaches that used to investigation biological functions and signaling pathways affected by differentially expressed messenger RNAs (mRNAs). The results of this study indicate an increase in the expression of HUR1 (p = 0.0001), CPSF7 (p = 0.02), and reduction of CSTF2 expression (p = 0.04). Also, an increase in the expression of OIP5-AS1 (p = 0.01) was observed in men less than 30 years old. We performed a comparative analysis of the long noncoding RNAs (lncRNAs), and then we ranked them as candidate biomarkers according to a decreasing area under the receiver operating characteristic (ROC) curve (AUC) and plotted the results. Dysregulation of lncRNA expression has been linked to diseases. Further studies on the HUR1 gene can be used as diagnostic tools for the identification of high-risk individuals in families with a history of disease before, during, and even after treatment. Our data uncovered the expression profiles of lncRNAs and mRNAs in MS patients, which will help delineate the molecular mechanisms in MS pathogenesis. However, further studies need to determine the precise role of these genes in the pathological process in MS.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  HUR1; OIP5-AS1; long noncoding RNA; multiple sclerosis

Mesh:

Substances:

Year:  2019        PMID: 30815864     DOI: 10.1002/jcp.28355

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

Review 1.  An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis.

Authors:  Marwa Kaisey; Ghazal Lashgari; Justyna Fert-Bober; Daniel Ontaneda; Andrew J Solomon; Nancy L Sicotte
Journal:  Curr Neurol Neurosci Rep       Date:  2022-10-21       Impact factor: 6.030

Review 2.  What do we know about the role of lncRNAs in multiple sclerosis?

Authors:  Viviana Nociti; Massimo Santoro
Journal:  Neural Regen Res       Date:  2021-09       Impact factor: 5.135

3.  Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis.

Authors:  Aya A Elkhodiry; Hend M El Tayebi
Journal:  Noncoding RNA Res       Date:  2021-12-07

4.  Identification of New Potential LncRNA Biomarkers in Hirschsprung Disease.

Authors:  Ana Torroglosa; Leticia Villalba-Benito; Raquel María Fernández; Berta Luzón-Toro; María José Moya-Jiménez; Guillermo Antiñolo; Salud Borrego
Journal:  Int J Mol Sci       Date:  2020-08-02       Impact factor: 5.923

5.  Identification of lncRNA-miRNA-mRNA regulatory network associated with primary open angle glaucoma.

Authors:  Minwen Zhou; Bing Lu; Wei Tan; Mingshui Fu
Journal:  BMC Ophthalmol       Date:  2020-03-16       Impact factor: 2.209

Review 6.  Long Non-Coding RNAs, Novel Offenders or Guardians in Multiple Sclerosis: A Scoping Review.

Authors:  Abbas Jalaiei; Mohammad Reza Asadi; Hani Sabaie; Hossein Dehghani; Jalal Gharesouran; Bashdar Mahmud Hussen; Mohammad Taheri; Soudeh Ghafouri-Fard; Maryam Rezazadeh
Journal:  Front Immunol       Date:  2021-12-07       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.